amifostine anhydrous has been researched along with Neoplasms in 156 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test the hypothesis that the cytoprotectant amifostine attenuates the thrombocytopenia produced by carboplatin, the authors performed a randomized trial comparing treatment with carboplatin alone versus the combination of amifostine and carboplatin." | 5.08 | Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. ( Adelstein, DJ; Budd, GT; Bukowski, RM; Capizzi, R; Ganapathi, R; McLain, D; Olencki, T; Pelley, R; Petrus, J; Zhang, J, 1997) |
| "The primary objective was to assess the efficacy of any medical intervention to prevent hearing loss in children with cancer treated with platinum-based therapy (that is including cisplatin, carboplatin and/or oxaliplatin) when compared to placebo, no additional treatment or a different protective medical intervention." | 4.90 | Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. ( van As, JW; van Dalen, EC; van den Berg, H, 2014) |
| " Professionals discussed a novel treatment (Irinotecan) for advanced colorectal cancers; a unique anticancer agent (Docetaxel) effective in hard-to-treat head and neck cancer; a highly active neoadjuvant chemotherapy regimen for operable breast cancer; and a cytoprotective agent (Amifostine) capable of protecting normal tissue from radiation and chemotherapeutic toxicity." | 3.69 | Highlights of the Eighth European Cancer Conference. ( Prescott, LM, 1995) |
| " The MTD for irinotecan administered in combination with cisplatin (30 mg/m(2)) was 50 mg/m(2)." | 2.71 | Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ( Bernstein, ML; Blaney, SM; Dubowy, RL; Hershon, L; McLeod, WD; Souid, AK; Sullivan, J, 2003) |
| "Patients with advanced solid tumors were randomized to gemcitabine-amifostine-cisplatin (GAP) or gemcitabine-cisplatin (GP) in Cycle 1 (C1) and then were crossed over to the other treatment in Cycle 2 (C2)." | 2.71 | Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies. ( Haigentz, M; Hamilton, A; Hochster, H; Kim, M; Lee, J; Macapinlac, M; Mirchandani, D; Muggia, FM; Pavlick, A; Sewak, S; Sorich, J; Volm, M, 2003) |
| " Four types of targeted adverse events were examined as to their occurrence and possible relationship with amifostine." | 2.71 | Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design. ( Chico, IM; Fullmer, K; Hirsch, RL; Samuels, MA, 2003) |
| "Melphalan was given in doses up to and including 300 mg/m(2)." | 2.71 | Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. ( Adams, VR; Badros, A; Brunner, J; Fenton, R; Filicko, J; Flomenberg, N; Grosso, D; Hale, GA; Howard, DS; Johnson, VP; Kniska, A; Marshall, KW; Meisenberg, B; Nath, R; Phillips, GL; Rapoport, AP; Reece, DE; Reed, E; Takebe, N; Vesole, DH; Wagner, JL, 2004) |
| "Etoposide was administered on Days 1 and 2 (150 mg/m(2))." | 2.70 | Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. ( Baruchel, S; Fouladi, M; Gammon, J; Grant, R; Greenberg, ML; Klein, J; Koren, G; Stempak, D, 2001) |
| "Thirty-one patients with solid tumors stratified according to pretreatment were randomized to receive VIP- or TIP-chemotherapy with or without amifostine (910 mg/m2) given as a short infusion prior to cisplatin." | 2.69 | A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. ( Bokemeyer, C; Fels, LM; Hartmann, JT; Kanz, L; Knop, S; Stolt, H, 2000) |
| "Thirty-one patients with solid tumors stratified according to pretreatment were randomized to receive cisplatin/ifosfamide-based chemotherapy with or without amifostine (1000 mg absolute) given as a short infusion prior to cisplatin." | 2.69 | The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. ( Bokemeyer, C; Fels, LM; Hartmann, JT; Kanz, L; Knop, S; Stolte, H; van Vangerow, A, 2000) |
| " An increase in the final half-life of ultrafilterable platinum was observed after treatment with cisplatin and amifostine (t1/2, 0." | 2.69 | Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. ( Fichtinger-Schepman, AM; Gall, HE; Korst, AE; van der Sterre, ML; van der Vijgh, WJ; Vermorken, JB, 1998) |
| " Compared with a control group of patients who received carboplatin alone, the patients receiving the combination had a longer final half-life of ultrafilterable platinum species [5." | 2.68 | Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. ( Eeltink, CM; Fichtinger-Schepman, AM; Korst, AE; van der Sterre, ML; van der Vijgh, WJ; Vermorken, JB, 1997) |
| "Melphalan was administered as a 5-min infusion using the previously defined MTD in heavily pretreated patients, 35 mg/m2, as the starting dose." | 2.68 | A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. ( Adamson, PC; Balis, FM; Belasco, JE; Berg, SL; Blaney, SM; Craig, C; Lange, B; Poplack, DG, 1995) |
| "Patients with advanced cancer first received a dose of 1000 mg/m2 cyclophosphamide intravenously and were observed for toxicity, principally myelosuppression." | 2.65 | Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide. ( Ayoob, MJ; Dritschilo, A; Smith, FP; Woolley, PV, 1983) |
| "Oral mucositis is a common complication of cancer treatment that may negatively impact the patient's cancer treatment outcome." | 2.52 | Mucositis: pathobiology and management. ( Sonis, ST; Villa, A, 2015) |
| "Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy." | 2.50 | MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. ( Barasch, A; Bowen, J; Elad, S; Elting, L; Epstein, J; Keefe, DM; Lalla, RV; McGuire, DB; Migliorati, C; Nicolatou-Galitis, O; Peterson, DE; Raber-Durlacher, JE; Sonis, ST, 2014) |
| "Nearly two thirds of all patients with cancer receive radiation therapy during the course of treatment, frequently resulting in acute skin and mucosal toxicities." | 2.49 | Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia. ( Pace, MB; Radvansky, LJ; Siddiqui, A, 2013) |
| "At the moment there is no evidence from individual studies in children with osteosarcoma and hepatoblastoma treated with different platinum analogues and dosage schedules which underscores the use of amifostine as an otoprotective intervention as compared to no additional treatment." | 2.48 | Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. ( van As, JW; van Dalen, EC; van den Berg, H, 2012) |
| "Dysgeusia is a common oral side effect of cancer therapy (radiotherapy, chemotherapy, or combined modality therapy) and often impacts negatively on quality of life." | 2.46 | A systematic review of dysgeusia induced by cancer therapies. ( Brennan, MT; Elting, LS; Hovan, AJ; Ohrn, KE; Spijkervet, FK; Stevenson-Moore, P; Wahlin, YB; Williams, PM, 2010) |
| "This list comprises genetic diseases (xeroderma pigmentosum, glucose-6-phosphate dehydrogenase deficiency), autoimmune disorders (vitiligo, scleroderma, thyroiditis, perforating collagenosis), metabolic diseases (diabetes mellitus), cardiovascular diseases, neuro/psychiatric diseases and other medical conditions (hypoglycemia, hepatic cirrhosis, alcoholism)." | 2.43 | Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases. ( Koukourakis, MI; Maltezos, E, 2006) |
| "radiotherapy plus amifostine for cancer treatment." | 2.43 | Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. ( Clark, LG; Clark, OA; Sasse, AD; Sasse, EC, 2006) |
| "Mucositis is a significant complication of cancer therapy, with important clinical and economic implications." | 2.43 | Amifostine in the management of radiation-induced and chemo-induced mucositis. ( Bensadoun, RJ; Keefe, D; Lalla, RV; Schubert, MM, 2006) |
| " Side effects related to the therapy may unfavorably influence quality of life for a short or long period of time, may cause the need to decrease the dosage or shorten the overall period of treatment or survival of the patient." | 2.42 | [Cytoprotective effects of amifostine in the treatment of tumors]. ( Burkon, P; Petýrek, P; Spurný, V, 2003) |
| " Also, the optimal dosage and schedule of amifostine in chemoradiation combinations have not yet been established." | 2.42 | Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. ( Andreassen, CN; Grau, C; Lindegaard, JC, 2003) |
| " Subcutaneous dosing is currently being assessed with the aim of improving ease of administration and potentially further improving tolerability." | 2.41 | Improved tolerability of amifostine with rapid infusion and optimal patient preparation. ( Boccia, R, 2002) |
| "The mechanism of action, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of amifostine are reviewed." | 2.40 | Amifostine for protection from antineoplastic drug toxicity. ( Foster-Nora, JA; Siden, R, 1997) |
| "Modern cancer therapy produces substantial acute and chronic toxicity which impairs quality of life and limits the effectiveness of treatment." | 2.40 | Toxicity antagonists in cancer therapy. ( Trotti, A, 1997) |
| "A number of novel anticancer agents have emerged during the past few decades, which show high activity in preclinical tumour models and promising activity in early trials in patients with solid tumours." | 2.39 | Emerging drug treatments for solid tumours. ( Pronk, LC; Schellens, JH; Verweij, J, 1996) |
| "Thrombocytopenia is a manifestation of hematopoietic toxicity that, at present, can be treated only with platelet transfusions." | 2.39 | Amifostine and chemotherapy-related thrombocytopenia. ( Budd, GT, 1996) |
| " It was shown that this compound can protect normal cells from the toxic effects of ionizing radiation and chemotheraphy without affecting the efficacy of the therapy." | 2.39 | [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy]. ( Chomiczewski, K; Jabłońska, H; Wrembel-Wargocka, J, 1996) |
| "By contrast, 60% of the tumors analyzed showed a loss of IAP expression in both epithelial cells and stroma, and only 10% to 15% of them demonstrated nuclear/cytoplasmic reactivity, which was confined to the epithelial cells." | 1.31 | Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. ( Giatromanolaki, A; Koukourakis, MI; Maltezos, E; Sivridis, E, 2002) |
| "A total of 117 cancer patients with carcinomas localized in pelvic organs, lung and head and neck were entered into this study." | 1.31 | Cytoprotective effect of amifostine in radiation-induced acute mucositis - a retrospective analysis. ( Balafouta, M; Kokakis, J; Kouloulias, V; Kouvaris, J; Matsopoulos, G; Miliadou, A; Vlahos, L, 2002) |
| " Eight patients were included in the study: six received paclitaxel in combination with epirubicin and cisplatin, and two received paclitaxel as a single agent." | 1.31 | Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors. ( Beijnen, JH; Hoekman, K; Huijskes, RV; Nannan Panday, VR; Rosing, H; Van den Brande, J; Verheijen, RH; Vermorken, JB, 2001) |
| "Mesna: (1) Mesna, dosed as detailed in these guidelines, is recommended to decrease the incidence of standard-dose ifosfamide-associated urothelial toxicity." | 1.30 | American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. ( Broder, G; Cohen, GI; Gradishar, WJ; Green, DM; Hensley, ML; Langdon, RJ; Lindley, C; Meropol, NJ; Mitchell, RB; Negrin, R; Pfister, DG; Schuchter, LM; Szatrowski, TP; Thigpen, JT; Von Hoff, D; Wasserman, TH; Winer, EP, 1999) |
| "Sixteen patients with advanced cancers had serial measurements of serum calcium and other studies of blood chemistry before and after taking the compound." | 1.27 | Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). ( Agus, ZS; Attie, M; Carmichael, K; Glick, J; Glover, D; Goldfarb, S; Kligerman, MM; Riley, L; Slatopolsky, E; Spar, B, 1983) |
| "Emesis was significantly influenced by infusion time; the long schedule caused a 57% incidence whereas the short schedule caused only a 28% incidence." | 1.27 | Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]. ( Glick, J; Glover, DJ; Hurwitz, S; Kligerman, MM; Norfleet, AL; Turrisi, AT; Weiler, C; Yuhas, JM, 1986) |
| "The pharmacokinetic properties of WR-2721 were investigated in 13 cancer patients given a 150 mg/M2 intravenous bolus dose of the drug." | 1.27 | Human pharmacokinetics of WR-2721. ( Bonner, HS; Glover, DJ; Kligerman, MM; Norfleet, AL; Shaw, LM; Turrisi, AT; Weiler, C, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (19.87) | 18.7374 |
| 1990's | 52 (33.33) | 18.2507 |
| 2000's | 54 (34.62) | 29.6817 |
| 2010's | 14 (8.97) | 24.3611 |
| 2020's | 5 (3.21) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Boutros, SW | 1 |
| Krenik, D | 1 |
| Holden, S | 1 |
| Unni, VK | 1 |
| Raber, J | 1 |
| Kaur, R | 1 |
| Lang, DK | 1 |
| Singh, H | 1 |
| Arora, A | 1 |
| Garg, N | 1 |
| Saini, B | 1 |
| King, M | 1 |
| Joseph, S | 1 |
| Albert, A | 1 |
| Thomas, TV | 1 |
| Nittala, MR | 1 |
| Woods, WC | 1 |
| Vijayakumar, S | 1 |
| Packianathan, S | 1 |
| Navarro-Ruiz, NE | 1 |
| Sevryugin, O | 1 |
| Kasvis, P | 1 |
| Vigano, M | 1 |
| Vigano, A | 1 |
| Rohilla, S | 1 |
| Dureja, H | 1 |
| Chawla, V | 1 |
| Freyer, DR | 1 |
| Brock, P | 1 |
| Knight, K | 1 |
| Reaman, G | 1 |
| Cabral, S | 1 |
| Robinson, PD | 1 |
| Sung, L | 1 |
| Radvansky, LJ | 1 |
| Pace, MB | 1 |
| Siddiqui, A | 1 |
| Lalla, RV | 3 |
| Bowen, J | 2 |
| Barasch, A | 1 |
| Elting, L | 1 |
| Epstein, J | 1 |
| Keefe, DM | 1 |
| McGuire, DB | 1 |
| Migliorati, C | 1 |
| Nicolatou-Galitis, O | 2 |
| Peterson, DE | 1 |
| Raber-Durlacher, JE | 1 |
| Sonis, ST | 2 |
| Elad, S | 2 |
| van As, JW | 2 |
| van den Berg, H | 2 |
| van Dalen, EC | 2 |
| Shaw, PJ | 2 |
| Nath, CE | 1 |
| Lazarus, HM | 1 |
| Villa, A | 1 |
| Mell, LK | 1 |
| Movsas, B | 2 |
| Hensley, ML | 3 |
| Hagerty, KL | 1 |
| Kewalramani, T | 1 |
| Green, DM | 2 |
| Meropol, NJ | 4 |
| Wasserman, TH | 4 |
| Cohen, GI | 2 |
| Emami, B | 1 |
| Gradishar, WJ | 2 |
| Mitchell, RB | 2 |
| Thigpen, JT | 2 |
| Trotti, A | 2 |
| von Hoff, D | 2 |
| Schuchter, LM | 6 |
| Cetingül, N | 1 |
| Midyat, L | 1 |
| Kantar, M | 1 |
| Demirağ, B | 1 |
| Aksoylar, S | 1 |
| Kansoy, S | 1 |
| Citrin, D | 1 |
| Cotrim, AP | 1 |
| Hyodo, F | 1 |
| Baum, BJ | 1 |
| Krishna, MC | 1 |
| Mitchell, JB | 1 |
| Hovan, AJ | 1 |
| Williams, PM | 1 |
| Stevenson-Moore, P | 1 |
| Wahlin, YB | 1 |
| Ohrn, KE | 1 |
| Elting, LS | 1 |
| Spijkervet, FK | 1 |
| Brennan, MT | 1 |
| Bourhis, J | 2 |
| Blanchard, P | 1 |
| Maillard, E | 1 |
| Brizel, DM | 3 |
| Buentzel, J | 1 |
| Langendijk, JA | 1 |
| Komaki, R | 1 |
| Swan Leong, S | 1 |
| Levendag, P | 1 |
| Pignon, JP | 2 |
| Koukourakis, MI | 7 |
| Sarri, T | 1 |
| Di Palma, M | 1 |
| Kouloulias, VE | 3 |
| Niscola, P | 1 |
| Riesenbeck, D | 1 |
| Stokman, M | 1 |
| Tissing, W | 1 |
| Yeoh, E | 1 |
| Duval, M | 1 |
| Daniel, SJ | 1 |
| Kouvaris, J | 1 |
| Kouloulias, V | 1 |
| Kokakis, J | 1 |
| Matsopoulos, G | 1 |
| Balafouta, M | 1 |
| Miliadou, A | 1 |
| Vlahos, L | 1 |
| Andreassen, CN | 1 |
| Grau, C | 1 |
| Lindegaard, JC | 2 |
| Souid, AK | 1 |
| Dubowy, RL | 1 |
| Blaney, SM | 2 |
| Hershon, L | 1 |
| Sullivan, J | 1 |
| McLeod, WD | 1 |
| Bernstein, ML | 1 |
| Boccia, R | 1 |
| Giatromanolaki, A | 2 |
| Sivridis, E | 1 |
| Maltezos, E | 2 |
| Phillips, GL | 2 |
| Pauwels, B | 1 |
| Korst, AE | 3 |
| de Pooter, CM | 1 |
| Lambrechts, HA | 1 |
| Pattyn, GG | 1 |
| Lardon, F | 1 |
| Vermorken, JB | 4 |
| Haigentz, M | 1 |
| Kim, M | 1 |
| Sorich, J | 1 |
| Lee, J | 1 |
| Hochster, H | 1 |
| Macapinlac, M | 1 |
| Mirchandani, D | 1 |
| Sewak, S | 1 |
| Pavlick, A | 1 |
| Volm, M | 1 |
| Hamilton, A | 1 |
| Muggia, FM | 1 |
| Colevas, AD | 1 |
| Brown, JM | 2 |
| Hahn, S | 1 |
| Mitchell, J | 1 |
| Camphausen, K | 1 |
| Coleman, CN | 1 |
| Overgaard, J | 1 |
| Simopoulos, C | 1 |
| Minopoulos, G | 1 |
| Patlakas, G | 1 |
| Polychronidis, A | 1 |
| Limberis, V | 1 |
| Romanides, K | 1 |
| Pitiacoudis, M | 1 |
| Manolas, C | 1 |
| Burkon, P | 1 |
| Petýrek, P | 1 |
| Spurný, V | 1 |
| Manola, KN | 1 |
| Terzoudi, GI | 1 |
| Dardoufas, CE | 1 |
| Malik, SI | 1 |
| Pantelias, GE | 1 |
| Samuels, MA | 1 |
| Chico, IM | 1 |
| Hirsch, RL | 1 |
| Fullmer, K | 1 |
| McCumber, LM | 1 |
| Meisenberg, B | 1 |
| Reece, DE | 1 |
| Adams, VR | 1 |
| Badros, A | 1 |
| Brunner, J | 1 |
| Fenton, R | 1 |
| Filicko, J | 1 |
| Grosso, D | 1 |
| Hale, GA | 1 |
| Howard, DS | 1 |
| Johnson, VP | 1 |
| Kniska, A | 1 |
| Marshall, KW | 1 |
| Nath, R | 1 |
| Reed, E | 1 |
| Rapoport, AP | 1 |
| Takebe, N | 1 |
| Vesole, DH | 1 |
| Wagner, JL | 1 |
| Flomenberg, N | 1 |
| Jakupec, MA | 1 |
| Galanski, M | 1 |
| Keppler, BK | 1 |
| Kouvaris, JR | 2 |
| Kokakis, JD | 1 |
| Kostakopoulos, A | 1 |
| Mallas, E | 1 |
| Metafa, A | 1 |
| Vlahos, LJ | 2 |
| Thephamongkhol, K | 1 |
| Sasse, AD | 1 |
| Clark, LG | 1 |
| Sasse, EC | 1 |
| Clark, OA | 1 |
| Block, KI | 1 |
| Gyllenhaal, C | 1 |
| Bensadoun, RJ | 1 |
| Schubert, MM | 2 |
| Keefe, D | 1 |
| Dest, VM | 1 |
| Rolleman, EJ | 1 |
| Forrer, F | 1 |
| Bernard, B | 1 |
| Bijster, M | 1 |
| Vermeij, M | 1 |
| Valkema, R | 1 |
| Krenning, EP | 1 |
| de Jong, M | 1 |
| Hogle, WP | 1 |
| Mao, J | 1 |
| Fatunase, OA | 1 |
| Marks, LB | 1 |
| Ozkaynak, MF | 1 |
| Sahdev, I | 1 |
| Gross, TG | 1 |
| Levine, JE | 1 |
| Cheerva, AC | 1 |
| Richards, MK | 1 |
| Rozans, MK | 1 |
| Kadota, RP | 1 |
| Murley, JS | 1 |
| Nantajit, D | 1 |
| Baker, KL | 1 |
| Kataoka, Y | 1 |
| Li, JJ | 1 |
| Grdina, DJ | 2 |
| Margulies, BS | 1 |
| Damron, TA | 1 |
| Allen, MJ | 1 |
| Nori, D | 1 |
| Kim, JH | 2 |
| Hilaris, BS | 1 |
| Chu, F | 1 |
| Glick, JH | 7 |
| Glover, D | 9 |
| Weiler, C | 9 |
| Norfleet, L | 1 |
| Yuhas, J | 2 |
| Kligerman, MM | 12 |
| Nagata, H | 1 |
| Yuhas, JM | 4 |
| Phillips, TL | 4 |
| Shaw, MT | 1 |
| Slavik, M | 1 |
| Chu, FC | 1 |
| Blumberg, AL | 1 |
| Nelson, DF | 1 |
| Amols, HI | 1 |
| Goodman, RL | 1 |
| Rude, JM | 1 |
| Mark, HL | 1 |
| Denekamp, J | 1 |
| Stewart, FA | 1 |
| Rojas, A | 1 |
| Riley, L | 1 |
| Carmichael, K | 1 |
| Spar, B | 1 |
| Glick, J | 3 |
| Agus, ZS | 1 |
| Slatopolsky, E | 1 |
| Attie, M | 1 |
| Goldfarb, S | 1 |
| Moldenhauer, H | 1 |
| Rose, H | 1 |
| Saul, G | 1 |
| Wolf, G | 1 |
| Kehrberg, G | 1 |
| Woolley, PV | 1 |
| Ayoob, MJ | 1 |
| Smith, FP | 1 |
| Dritschilo, A | 1 |
| Travis, EL | 1 |
| Peters, LJ | 1 |
| Capizzi, RL | 5 |
| Oster, W | 2 |
| Adamson, PC | 1 |
| Balis, FM | 1 |
| Belasco, JE | 1 |
| Lange, B | 1 |
| Berg, SL | 1 |
| Craig, C | 1 |
| Poplack, DG | 1 |
| Lewis, C | 1 |
| Budd, GT | 5 |
| Lorenzi, V | 1 |
| Ganapathi, R | 4 |
| Adelstein, D | 2 |
| Pelley, R | 2 |
| Olencki, T | 2 |
| McLain, D | 3 |
| Bukowski, RM | 6 |
| O'Rourke, N | 1 |
| McCloskey, E | 1 |
| Kanis, J | 1 |
| Bauer, L | 1 |
| Murthy, S | 2 |
| Weick, J | 1 |
| Gibson, V | 1 |
| Sergi, J | 1 |
| Spencer, CM | 1 |
| Goa, KL | 1 |
| Schellens, JH | 1 |
| Pronk, LC | 1 |
| Verweij, J | 1 |
| Alberts, DS | 2 |
| Capizzi, R | 2 |
| Tannehill, SP | 1 |
| Mehta, MP | 2 |
| Bleyer, WA | 1 |
| Lenoble, M | 1 |
| Foster-Nora, JA | 1 |
| Siden, R | 1 |
| Wrembel-Wargocka, J | 1 |
| Jabłońska, H | 1 |
| Chomiczewski, K | 1 |
| Adelstein, DJ | 1 |
| Petrus, J | 1 |
| Zhang, J | 1 |
| Selvaratnam, G | 1 |
| Philips, RH | 1 |
| Mohamed, AK | 1 |
| Radzi, A | 1 |
| van der Sterre, ML | 2 |
| Gall, HE | 1 |
| Fichtinger-Schepman, AM | 2 |
| van der Vijgh, WJ | 2 |
| Viele, CS | 1 |
| Holmes, BC | 1 |
| Griggs, JJ | 1 |
| Santolaya-Perrin, R | 1 |
| Castillo-Romera, I | 1 |
| Requena-Caturla, T | 1 |
| Curran, WJ | 1 |
| Eeltink, CM | 1 |
| Chvetzoff, G | 1 |
| Bonnotte, B | 1 |
| Chauffert, B | 1 |
| Wasserman, T | 1 |
| Werner-Wasik, M | 1 |
| Provinciali, M | 1 |
| Ciavattini, A | 1 |
| Di Stefano, G | 1 |
| Argentati, K | 1 |
| Garzetti, GG | 1 |
| Lindley, C | 1 |
| Broder, G | 1 |
| Langdon, RJ | 1 |
| Negrin, R | 1 |
| Szatrowski, TP | 1 |
| Winer, EP | 2 |
| Pfister, DG | 1 |
| Korzon, M | 1 |
| Popadiuk, S | 1 |
| Plata-Nazar, K | 1 |
| Gołebiewski, J | 1 |
| Szarszewski, A | 1 |
| Czauderna, P | 1 |
| Stoba, C | 1 |
| Hartmann, JT | 3 |
| Knop, S | 3 |
| Fels, LM | 3 |
| van Vangerow, A | 1 |
| Stolte, H | 2 |
| Kanz, L | 3 |
| Bokemeyer, C | 4 |
| Crawford, J | 1 |
| Foote, M | 1 |
| Morstyn, G | 1 |
| Rasey, JS | 1 |
| Kakolyris, S | 1 |
| Froudarakis, M | 1 |
| Georgoulias, V | 1 |
| Retalis, G | 1 |
| Bahlitzanakis, N | 1 |
| Chauncey, TR | 1 |
| Gooley, TA | 1 |
| Lloid, ME | 1 |
| Lilleby, K | 1 |
| Holmberg, L | 1 |
| Bensinger, WI | 1 |
| Stolt, H | 1 |
| von Vangerow, A | 1 |
| Awasthy, BS | 1 |
| Julka, PK | 1 |
| Agarwal, S | 1 |
| Nair, O | 1 |
| Bhamrah, R | 1 |
| Rath, GK | 1 |
| Prescott, LM | 1 |
| Büntzel, J | 1 |
| Wagner, W | 1 |
| Van den Brande, J | 1 |
| Nannan Panday, VR | 1 |
| Hoekman, K | 1 |
| Rosing, H | 1 |
| Huijskes, RV | 1 |
| Verheijen, RH | 1 |
| Beijnen, JH | 1 |
| Fouladi, M | 1 |
| Stempak, D | 1 |
| Gammon, J | 1 |
| Klein, J | 1 |
| Grant, R | 1 |
| Greenberg, ML | 1 |
| Koren, G | 1 |
| Baruchel, S | 1 |
| Jantunen, E | 1 |
| Puistola, U | 1 |
| Chapman, JD | 1 |
| Urtasun, RC | 2 |
| Tsukiyama, I | 1 |
| Luginbuhl, WE | 1 |
| McCulloch, W | 1 |
| Scheffler, BJ | 1 |
| Schein, PS | 2 |
| Gandara, DR | 1 |
| Perez, EA | 1 |
| Weibe, V | 1 |
| De Gregorio, MW | 1 |
| Mahaney, FX | 1 |
| Turrisi, AT | 3 |
| Glover, DJ | 2 |
| Hurwitz, S | 1 |
| Norfleet, AL | 4 |
| Barkley, T | 1 |
| Rubin, P | 1 |
| Grabelsky, S | 1 |
| Fox, K | 2 |
| Cannon, L | 1 |
| Rizzoli, R | 1 |
| Bonjour, JP | 1 |
| Shaw, LM | 2 |
| Turrisi, A | 3 |
| Brown, DQ | 1 |
| Bonner, HS | 2 |
| Nagy, B | 1 |
| Sigdestad, CP | 1 |
| Fox, KR | 1 |
| Kumar, S | 1 |
| Hurowitz, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Incorporating a Randomized Assessment of Sodium Thiosulfate as Otoprotection for Children With Localized Disease, and Respons[NCT04478292] | Phase 3 | 330 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic Hematopoietic Stem Cell Transplantation.[NCT06071637] | Phase 3 | 84 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | ||
| Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study[NCT03203733] | 182 participants (Actual) | Interventional | 2017-06-12 | Completed | |||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Opioid Therapy vs Multimodal Analgesia in Head and Neck Cancer: A Randomized Clinical Trial[NCT04221165] | Phase 2 | 62 participants (Anticipated) | Interventional | 2020-08-04 | Recruiting | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| The Effectiveness of Topical Oral Vitamin D Gel in Prevention of Radiation-induced Oral Mucositis[NCT04308161] | Phase 2 | 45 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
| The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570] | Phase 2 | 40 participants (Actual) | Interventional | 2018-01-12 | Completed | ||
| Effect of Prophylactic Use of Oral Vitamin D and Zinc in Management of the Severity of Radiation Induced Oral Mucositis of Head and Neck Cancer Patients[NCT06100692] | 100 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| A Phase II Study to Evaluate Oral Chlorophyllin in Hemorrhagic Cystitis Secondary to Radiation Therapy for Pelvic Malignancies[NCT05348239] | Phase 2 | 24 participants (Anticipated) | Interventional | 2022-03-26 | Recruiting | ||
| Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment: a Prospective Cohort Study on Patients Affected by Breast Cancer[NCT03210441] | 204 participants (Anticipated) | Observational | 2014-05-06 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
78 reviews available for amifostine anhydrous and Neoplasms
| Article | Year |
|---|---|
Repurposing of Various Current Medicines as Radioprotective Agents.
Topics: Amifostine; Humans; Neoplasms; Radiation-Protective Agents | 2023 |
Use of Amifostine for Cytoprotection during Radiation Therapy: A Review.
Topics: Amifostine; Clinical Trials as Topic; Cytoprotection; Disease Management; Humans; Neoplasms; Organ S | 2020 |
Prevention of Platinum-Induced Hearing Loss in Children with Cancer.
Topics: Amifostine; Humans; Neoplasms; Ototoxicity; Platinum; Practice Guidelines as Topic; Thiosulfates | 2020 |
Taste and smell disturbances in cancer patients: a scoping review of available treatments.
Topics: Adult; Amifostine; Carnosine; Dronabinol; Humans; Neoplasms; Nutritional Status; Olfaction Disorders | 2021 |
Cytoprotective Agents to Avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review.
Topics: Amifostine; Antineoplastic Agents; Cytoprotection; Drug-Related Side Effects and Adverse Reactions; | 2019 |
Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.
Topics: Acetylcysteine; Adolescent; Amifostine; Anti-Inflammatory Agents; Antineoplastic Agents; Chelating A | 2019 |
Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia.
Topics: Administration, Topical; Amifostine; Analgesics; Antineoplastic Protocols; Combined Modality Therapy | 2013 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
Topics: Adolescent; Amifostine; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Child; Child, Preschool; | 2014 |
Not too little, not too much-just right! (Better ways to give high dose melphalan).
Topics: Amifostine; Antineoplastic Agents, Alkylating; Fibroblast Growth Factor 7; Hematopoietic Stem Cell T | 2014 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine.
Topics: Amifostine; Female; Genital Neoplasms, Female; Head and Neck Neoplasms; Humans; Neoplasms; Radiation | 2008 |
Radioprotectors and mitigators of radiation-induced normal tissue injury.
Topics: Amifostine; Animals; Antioxidants; Cyclic N-Oxides; DNA Damage; Fibroblast Growth Factor 7; Free Rad | 2010 |
A systematic review of dysgeusia induced by cancer therapies.
Topics: Amifostine; Dysgeusia; Humans; Neoplasms; Prevalence; Quality of Life; Zinc Sulfate | 2010 |
Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-S | 2011 |
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
Topics: Adolescent; Amifostine; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Child; Child, Preschool; | 2012 |
Systematic review of amifostine for the management of oral mucositis in cancer patients.
Topics: Administration, Topical; Amifostine; Evidence-Based Medicine; Humans; Infusions, Intravenous; Inject | 2013 |
Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity.
Topics: Amifostine; Antineoplastic Agents; Cisplatin; Ear Diseases; Humans; Neoplasms; Radiation-Protective | 2012 |
Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy.
Topics: Amifostine; Combined Modality Therapy; Dose-Response Relationship, Radiation; Europe; Humans; Neopla | 2003 |
Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
Topics: Amifostine; Antineoplastic Agents; Clinical Trials as Topic; Cytoprotection; Humans; Infusions, Intr | 2002 |
The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytoprotection | 2002 |
Development of investigational radiation modifiers.
Topics: Amifostine; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phas | 2003 |
[Cytoprotective effects of amifostine in the treatment of tumors].
Topics: Amifostine; Antineoplastic Agents; Cytoprotection; Humans; Neoplasms; Radiation-Protective Agents | 2003 |
Amifostine: is there evidence of tumor protection?
Topics: Amifostine; Animals; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dog | 2003 |
The effect of cytoprotective agents in platinum anticancer therapy.
Topics: Amifostine; Antineoplastic Agents; Cell Survival; Glutathione; Humans; Mesna; Neoplasms; Platinum Co | 2004 |
Randomized trials of amifostine and radiotherapy: effect on survival?
Topics: Amifostine; Combined Modality Therapy; Cytoprotection; Databases as Topic; Humans; Meta-Analysis as | 2004 |
Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
Topics: Amifostine; Cystitis; Deglutition Disorders; Esophagitis; Humans; Neoplasms; Radiation Injuries; Rad | 2006 |
Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases.
Topics: Amifostine; Autoimmune Diseases; Combined Modality Therapy; Comorbidity; Genetic Diseases, Inborn; H | 2006 |
Commentary: the pharmacological antioxidant amifostine -- implications of recent research for integrative cancer care.
Topics: Amifostine; Antioxidants; Clinical Trials as Topic; Combined Modality Therapy; Drug-Related Side Eff | 2005 |
Amifostine in the management of radiation-induced and chemo-induced mucositis.
Topics: Amifostine; Antineoplastic Agents; Combined Modality Therapy; Esophagitis; Evidence-Based Medicine; | 2006 |
Radioprotectants: adding quality of life to survivorship?
Topics: Amifostine; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; O | 2006 |
Amifostine: the first selective-target and broad-spectrum radioprotector.
Topics: Amifostine; Humans; Mucositis; Neoplasms; Radiation-Protective Agents; Radiotherapy; Treatment Outco | 2007 |
Cytoprotective agents used in the treatment of patients with cancer.
Topics: Amifostine; Antineoplastic Agents; Cytoprotection; Fibroblast Growth Factors; Glutamine; Humans; Mes | 2007 |
Cytoprotection for radiation-associated normal tissue injury.
Topics: Amifostine; Clinical Trials as Topic; Cytoprotection; Humans; Neoplasms; Radiation Injuries; Radiati | 2008 |
Sensitizers and protectors in clinical oncology.
Topics: Alkylating Agents; Amifostine; Animals; Drug Synergism; Humans; Mice; Misonidazole; Neoplasms; Neopl | 1981 |
Chemical radiation sensitizers and protectors: recent developments.
Topics: Amifostine; Cysteamine; Cysteine; DNA, Neoplasm; Humans; Neoplasms; Nitroimidazoles; Nucleic Acid Co | 1981 |
[Modification of the radiation effects for overcoming radiation-resistant hypoxic tumor tissue].
Topics: Amifostine; Animals; Central Nervous System Diseases; Dogs; Humans; Hyperthermia, Induced; In Vitro | 1983 |
Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Topics: Amifostine; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Humans; Ne | 1995 |
A review of the use of chemoprotectants in cancer chemotherapy.
Topics: Adrenocorticotropic Hormone; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1994 |
Amifostine: potential for clinically useful cytoprotection.
Topics: Amifostine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical | 1994 |
Radiotherapeutic studies with amifostine (Ethyol).
Topics: Amifostine; Animals; Cell Survival; Clinical Trials as Topic; Colony-Forming Units Assay; Humans; Ne | 1994 |
Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Topics: Amifostine; Antineoplastic Agents; Cell Survival; Clinical Trials as Topic; Female; Humans; Male; Ne | 1994 |
Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Neopla | 1995 |
Emerging drug treatments for solid tumours.
Topics: Amifostine; Antineoplastic Agents; Aziridines; Deoxycytidine; Gemcitabine; Humans; Indolequinones; I | 1996 |
Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies.
Topics: Amifostine; Animals; Antineoplastic Agents; Cells; Combined Modality Therapy; Humans; Mercaptoethyla | 1996 |
Amifostine and chemotherapy-related thrombocytopenia.
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Drug Interactions; Drug Therapy, Combination; Humans | 1996 |
Amifostine and radiation therapy: past, present, and future.
Topics: Amifostine; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Neopl | 1996 |
Future development of amifostine in cancer treatment.
Topics: Adult; Amifostine; Antineoplastic Agents; Child; Clinical Trials, Phase II as Topic; Clinical Trials | 1996 |
[Amifostine: current and future applications in cytoprotection].
Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow; Disease Models, Animal; Drug Tolerance; Hem | 1996 |
The need for cytoprotection.
Topics: Amifostine; Antineoplastic Agents; Cell Death; Humans; Neoplasms | 1996 |
Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
Topics: Amifostine; Animals; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Drug Administration | 1996 |
Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.
Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Clinical Trials as Topic; Humans; Mice; Neo | 1996 |
Amifostine for protection from antineoplastic drug toxicity.
Topics: Amifostine; Antineoplastic Agents; Clinical Trials as Topic; Hearing; Humans; Kidney; Melanoma; Neop | 1997 |
[Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
Topics: Amifostine; Antineoplastic Agents; Hematologic Diseases; Humans; Kidney Diseases; Neoplasms; Nervous | 1996 |
Toxicity antagonists in cancer therapy.
Topics: Amifostine; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agent | 1997 |
Adverse effects of cytotoxics-platinum agents.
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Kidney Diseases; Neoplasms; Perip | 1997 |
Amifostine: drug profile and nursing implications of the first pancytoprotectant.
Topics: Amifostine; Antineoplastic Agents; Cytoprotection; Humans; Nausea; Neoplasms; Premedication | 1998 |
Reducing the toxicity of anticancer therapy: new strategies.
Topics: Amifostine; Antineoplastic Agents; Cytoprotection; Dose-Response Relationship, Drug; Humans; Neoplas | 1998 |
Radiation-induced toxicities: the role of radioprotectants.
Topics: Amifostine; Clinical Trials as Topic; Dose Fractionation, Radiation; Humans; Neoplasms; Radiation Pr | 1998 |
[Anticancer chemotherapy. Prevention of toxicity].
Topics: Amifostine; Antidotes; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Protocols; Female; He | 1998 |
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Topics: Amifostine; Animals; Antineoplastic Agents; Cytoprotection; Drug Evaluation, Preclinical; Humans; Me | 1999 |
Radioprotective effects of amifostine.
Topics: Amifostine; Clinical Trials as Topic; Cytoprotection; Humans; Neoplasms; Radiation-Protective Agents | 1999 |
Amifostine and combined-modality therapeutic approaches.
Topics: Amifostine; Clinical Trials as Topic; Combined Modality Therapy; Cytoprotection; Female; Head and Ne | 1999 |
Future development of amifostine as a radioprotectant.
Topics: Amifostine; Anticarcinogenic Agents; Antimutagenic Agents; Antineoplastic Agents; Clinical Trials as | 1999 |
Hematopoietic growth factors in cancer chemotherapy.
Topics: Amifostine; Animals; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage C | 1999 |
Amifostine.
Topics: Amifostine; Animals; Clinical Trials as Topic; Humans; Neoplasms; Neoplasms, Experimental; Radiation | 1999 |
Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
Topics: Amifostine; Animals; Antineoplastic Agents; Clinical Trials as Topic; Cytoprotection; Humans; Neopla | 2000 |
The role of amifostine as a radioprotector.
Topics: Amifostine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, | 2001 |
[Amifostine as a supporting treatment during cancer therapy].
Topics: Amifostine; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Radiation-Protective | 1999 |
Amifostine in clinical oncology: current use and future applications.
Topics: Amifostine; Animals; Humans; Neoplasms; Radiation-Protective Agents | 2002 |
The current status of toxicity protectants in cancer therapy.
Topics: Amifostine; Antineoplastic Agents; Clinical Trials as Topic; Cytokines; Ditiocarb; Drug Evaluation, | 1992 |
New protective agents for bone marrow in cancer therapy.
Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow; Humans; Neoplasms | 1991 |
Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Topics: Adrenocorticotropic Hormone; Amifostine; Anticonvulsants; Cisplatin; Ditiocarb; Humans; Inactivation | 1991 |
[PTH-like tumor peptide and malignant hypercalcemia].
Topics: Amifostine; Bone Resorption; Calcium; Humans; Hypercalcemia; Neoplasm Proteins; Neoplasms; Parathyro | 1989 |
Pharmacokinetics of WR-2721.
Topics: Amifostine; Animals; Humans; Hydrolysis; Neoplasms; Neoplasms, Experimental; Organothiophosphorus Co | 1988 |
Radioprotectors in treatment therapy to reduce risk in secondary tumor induction.
Topics: Amifostine; Animals; Cell Transformation, Neoplastic; Humans; Mercaptoethylamines; Neoplasms; Neopla | 1988 |
Sensitizers and protectors in radiotherapy.
Topics: Amifostine; Animals; Aziridines; Clinical Trials as Topic; Drug Evaluation; Etanidazole; Glutathione | 1985 |
Studies on radioprotectors in mammals and their possible use in radiotherapy--a summary.
Topics: Amifostine; Amino Acids, Sulfur; Animals; Drug Combinations; Humans; Mice; Neoplasms; Organothiophos | 1985 |
25 trials available for amifostine anhydrous and Neoplasms
| Article | Year |
|---|---|
Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; | 2003 |
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 2003 |
Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design.
Topics: Aged; Amifostine; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Radiation | 2003 |
Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study.
Topics: Adult; Aged; Amifostine; Cohort Studies; Disease-Free Survival; Drug-Related Side Effects and Advers | 2004 |
A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplan | 2008 |
Radiosensitizers and protectors.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Human | 1984 |
Rationale for initial clinical trials and future development of radioprotectors.
Topics: Amifostine; Animals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dose-Response Relat | 1980 |
Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide.
Topics: Adult; Aged; Amifostine; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; | 1983 |
A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Prescho | 1995 |
Phase I study of WR-2721 and carboplatin.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans | 1993 |
[Amifostine: current and future applications in cytoprotection].
Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow; Disease Models, Animal; Drug Tolerance; Hem | 1996 |
Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents; Bone Marrow; Carboplatin; Female; | 1997 |
Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Cisplatin; DNA Adducts; Drug Interactions; Female; H | 1998 |
Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Dose-Response Relationship, Drug; Half-Life | 1997 |
In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Apoptosis; Female; Humans; Lymphocytes; Middle Aged; | 1999 |
[Ethyol (amifostine): application trial in pediatric oncology].
Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dos | 1998 |
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfa | 2000 |
Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modal | 2000 |
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Gl | 2000 |
A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2001 |
Effect of amifostine on toxicities associated with salvage combination chemotherapy.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female | 2001 |
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, P | 2001 |
WR-2721: a chemotherapy and radiation-protective agent.
Topics: Amifostine; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Organothiophosphorus | 1990 |
Clinical trials of WR-2721 and cis-platinum.
Topics: Adult; Aged; Amifostine; Cisplatin; Diuresis; Drug Evaluation; Drug Therapy, Combination; Female; Hu | 1989 |
Sensitizers and protectors in radiotherapy.
Topics: Amifostine; Animals; Aziridines; Clinical Trials as Topic; Drug Evaluation; Etanidazole; Glutathione | 1985 |
55 other studies available for amifostine anhydrous and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Common cancer treatments targeting DNA double strand breaks affect long-term memory and relate to immediate early gene expression in a sex-dependent manner.
Topics: Amifostine; Animals; DNA; DNA Breaks, Double-Stranded; Etoposide; Female; Genes, Immediate-Early; Ma | 2022 |
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Topics: Amifostine; Antineoplastic Agents; Fibroblast Growth Factor 7; Humans; Mesna; Neoplasms; Practice Gu | 2009 |
Cytoprotective effects of amifostine in the treatment of childhood malignancies.
Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Com | 2009 |
Radiation damage and radioprotectants: new concepts in the era of molecular medicine.
Topics: Amifostine; Bystander Effect; Humans; Neoplasms; Radiation Injuries; Radiation-Protective Agents | 2012 |
Cytoprotective effect of amifostine in radiation-induced acute mucositis - a retrospective analysis.
Topics: Acute Disease; Adult; Aged; Amifostine; Esophagus; Female; Gastric Mucosa; Humans; Male; Middle Aged | 2002 |
Proceedings of the 2nd International Cytoprotection Investigators' Congress. June 6-9, 2002. St Thomas, US Virgin Islands, USA.
Topics: Amifostine; Animals; Breast Neoplasms; Cytoprotection; Female; Head and Neck Neoplasms; Humans; Lung | 2002 |
Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity.
Topics: Alkaline Phosphatase; Amifostine; Antigens, Neoplasm; Biomarkers, Tumor; Breast; Breast Neoplasms; C | 2002 |
The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro.
Topics: Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2003 |
Has the time come for routine use of amifostine in clinical radiotherapy practice?
Topics: Amifostine; Clinical Trials as Topic; Humans; Neoplasms; Radiation-Protective Agents; Radiotherapy | 2003 |
Does amifostine have a role in chemoradiation treatment?
Topics: Amifostine; Combined Modality Therapy; Humans; Neoplasms; Radiation Injuries; Radiation-Protective A | 2003 |
Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Routes; | 2003 |
Radioprotective effect of amifostine on cells from cancer prone patients and healthy individuals studied by the G2 and PCC assays.
Topics: Amifostine; Ataxia Telangiectasia; Cell Line, Tumor; Chromosome Aberrations; Cytogenetic Analysis; G | 2003 |
Proceedings of the 3rd International Cytoprotection Investigators' Congress. May 15-18, 2003, Nevis, West Indies.
Topics: Amifostine; Animals; Humans; Neoplasms; Radiation Injuries; Radiation-Protective Agents | 2003 |
The potential influence of cell protectors for dose escalation in cancer therapy: an analysis of amifostine.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Radiation; Humans; N | 2004 |
Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis.
Topics: Amifostine; Female; Humans; Injections, Intravenous; Male; Middle Aged; Mucous Membrane; Neoplasms; | 2004 |
Proceedings of the Fourth International Cytoprotection Investigators' Congress. May 2004. Philadelphia, Pennsylvania, USA.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modal | 2004 |
New approaches to preventing xerostomia.
Topics: Amifostine; Cytoprotection; Humans; Muscarinic Agonists; Neoplasms; Pilocarpine; Quinuclidines; Radi | 2006 |
Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
Topics: Amifostine; Animals; Body Weight; Creatinine; Kidney; Lysine; Male; Neoplasms; Octreotide; Organomet | 2007 |
Maintenance of manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by repeated administration of the free thiol form of amifostine.
Topics: Amifostine; Animals; Cells, Cultured; Endothelial Cells; Humans; Mice; Neoplasms; RNA, Small Interfe | 2008 |
The differential effects of the radioprotectant drugs amifostine and sodium selenite treatment in combination with radiation therapy on constituent bone cells, Ewing's sarcoma of bone tumor cells, and rhabdomyosarcoma tumor cells in vitro.
Topics: Amifostine; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitum | 2008 |
Phase I controlled trials of WR-2721 and cyclophosphamide.
Topics: Adult; Aged; Agranulocytosis; Amifostine; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combinati | 1984 |
Phase I trials of WR-2721 and cis-platinum.
Topics: Amifostine; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Humans; Kidney Diseases; Neoplasm | 1984 |
Studies on sulfhydryl radioprotectors with low toxicities.
Topics: Amifostine; Animals; Cell Survival; Cells, Cultured; Humans; Male; Mice; Neoplasms; Radiation-Protec | 1980 |
A more general role for WR-2721 in cancer therapy.
Topics: Amifostine; Animals; Cisplatin; Female; Mammary Neoplasms, Experimental; Neoplasms; Organothiophosph | 1980 |
Phase I clinical studies with WR-2721.
Topics: Amifostine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Humans; | 1980 |
Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum.
Topics: Amifostine; Blood Pressure; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Eval | 1981 |
Sequential regional hyperthermia: a possible answer for the treatment of cancer.
Topics: Amifostine; Animals; Glucose; Hot Temperature; Humans; Neoplasm Metastasis; Neoplasms | 1982 |
Is the outlook grey for WR-2721 as a clinical radioprotector?
Topics: Amifostine; Animals; Humans; Neoplasms; Organothiophosphorus Compounds; Radiation-Protective Agents | 1983 |
Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent).
Topics: Amifostine; Animals; Antineoplastic Agents; Calcium; Cattle; Drug Evaluation; Humans; Hydrogen-Ion C | 1983 |
Radiobiology and clinical radiotherapy.
Topics: Amifostine; Animals; Fast Neutrons; Humans; Mice; Neoplasms; Radiation Dosage; Radiation Injuries; R | 1984 |
WR-2721 and hypocalcemia.
Topics: Amifostine; Humans; Hypercalcemia; Neoplasms | 1994 |
Introduction: applications of amifostine in cancer treatment.
Topics: Amifostine; Combined Modality Therapy; Humans; Neoplasms; Radiation-Protective Agents | 1996 |
Guidelines for the administration of amifostine.
Topics: Amifostine; Combined Modality Therapy; Humans; Neoplasms; Practice Guidelines as Topic; Premedicatio | 1996 |
Current approaches in cytoprotection: the role of amifostine (Ethyol) in altering and ameliorating toxicities in cancer therapy.
Topics: Amifostine; Antineoplastic Agents; Humans; Neoplasms | 1996 |
[Optimal tumor therapy with cytoprotection by ETHYOL (Amifostine). 32nd Annual Session of the American Society of Clinical Oncology in Philadelphia 18-21 May 1996].
Topics: Amifostine; Cytoprotection; Humans; Neoplasms; Radiation-Protective Agents | 1996 |
Indications for use of amifostine.
Topics: Amifostine; Cytoprotection; Humans; Neoplasms; Radiation-Protective Agents | 1998 |
Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.
Topics: Amifostine; Antineoplastic Agents; Combined Modality Therapy; Cytoprotection; Humans; Neoplasms; Pro | 1999 |
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Topics: Adult; Amifostine; Antineoplastic Agents; Cardiovascular Agents; Humans; Mesna; Neoplasms; Protectiv | 1999 |
Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Topics: Adult; Aged; Amifostine; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2000 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Mo | 1995 |
[Recommendations of the Working Group 'Supportive Massnahmen in der Onkologie' concerning the Clinical Use of Cytoprotectives].
Topics: Amifostine; Antineoplastic Agents; Cell Survival; Clinical Trials as Topic; Cytoprotection; Humans; | 2001 |
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Interactions; Epirubicin | 2001 |
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
Topics: Amifostine; Antineoplastic Agents; Chelating Agents; Humans; Mesna; Neoplasms; Protective Agents; Ra | 2002 |
The application in radiation therapy of substances which modify cellular radiation response.
Topics: Amifostine; Animals; Drug Evaluation; Drug Therapy, Combination; Humans; Metronidazole; Neoplasms; N | 1977 |
[Radioprotective effects of YM-08310 on normal and malignant tissues (author's transl)].
Topics: Amifostine; Animals; Male; Mice; Neoplasms; Organothiophosphorus Compounds; Radiation-Protective Age | 1978 |
Supportive care drug studies: some promising, some not.
Topics: Amifostine; Antineoplastic Agents; Cachexia; Clodronic Acid; Fractures, Spontaneous; Humans; Hydrazi | 1992 |
Agent designed for war now in doctors' armamentarium.
Topics: Amifostine; Humans; Neoplasms; Organothiophosphorus Compounds; Radiation-Protective Agents | 1990 |
Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid].
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Drug Evaluation; Female; Humans; Hypotension; Infusi | 1986 |
Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy.
Topics: Adolescent; Adult; Aged; Amifostine; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Infu | 1988 |
Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy.
Topics: Alkylating Agents; Amifostine; Cisplatin; Cyclophosphamide; Drug Evaluation; Humans; Neoplasms; Orga | 1988 |
WR-2721 protects against the hematologic toxicity of cyclophosphamide.
Topics: Amifostine; Bone Marrow; Cyclophosphamide; Humans; Neoplasms; Organothiophosphorus Compounds | 1986 |
WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.
Topics: Aged; Amifostine; Cyclophosphamide; Drug Evaluation; Humans; Leukopenia; Middle Aged; Neoplasms; Org | 1986 |
Phase I/II trials of WR-2721 and cis-platinum.
Topics: Amifostine; Cisplatin; Drug Evaluation; Humans; Kidney; Kidney Diseases; Neoplasms; Organothiophosph | 1986 |
Human pharmacokinetics of WR-2721.
Topics: Amifostine; Humans; Kinetics; Mercaptoethylamines; Neoplasms; Organothiophosphorus Compounds; Radiat | 1986 |